20 Mar 2023

Race for a first-to-market therapy for NASH heats up

The race for a first-to-market therapy in non-alcoholic steatohepatitis (NASH) has been a marathon, with many companies facing numerous setbacks and failures. However, it appears that two companies have gained…

[ajax_load_more post_type="post" taxonomy="category" taxonomy_terms="comment" taxonomy_operator="IN" images_loaded="true" posts_per_page="20" offset="7" pause="true" scroll="false" button_label="Load More Stories"]